In October 2024, I succeeded Dr. Koichi Node as the 13th President of the Japanese Society of Hypertension (JSH). Hypertension remains a leading risk factor for stroke, cardiovascular disease and kidney disease, and the JSH has made significant contributions to controlling this condition. Recently, under the slogan ‘Healthy 100-year life in hypertensive patients’, we have been actively advancing the ‘JSH Future Plan’ (Fig. 1) [1, 2]. To accelerate these efforts, the JSH plans to focus on three main pillars: digital hypertension research, implementation science in hypertension, and internationalization (Fig. 2). Each of these pillars is described in detail below.
Japanese Society of Hypertension Future Plan. Reproduced, with permission, from Node et al. Hypertens Res 2018; 41: 989–990 [1]
Three pillars of JSH activity 2024–2026 in the information network era. AI artificial intelligence, BP blood pressure, HOPE Asia Network Hypertension Cardiovascular Outcome Prevention and Evidence in Asia Network, JSH Japanese Society of Hypertension, ICT information and communication technology, J-DOME Japan Medical Association Database of Clinical Medicine
Digital hypertension research
Digital hypertension is an emerging research field that leverages blood pressure (BP) as a master biomarker, evolving rapidly within the digital information era [3]. By capturing all relevant biological data—genetic, environmental, behavioral, and habitual—utilizing interconnected networks and synchronizing these data with BP fluctuations over time, we can generate evidence for personalized anticipation medicine and add value to the comprehensive prevention of hypertension and healthcare in general. Key research themes include: (1) the research and development of wearable BP monitors and vascular function assessment devices; (2) collaborative engineering and medical research on information and communication technology (ICT)-linked information systems; (3) data science research utilizing artificial intelligence (AI); and (4) the development of BP data management systems and digital therapeutics via apps [4,5,6,7,8,9]. Additionally, the JSH will focus on establishing guidelines and standardizing the new devices and ICT systems that are required for societal implementation of effective initiatives, taking into account consideration of international harmonization [10].
Implementation science in hypertension
Hypertension treatment guidelines were released by the European Society of Hypertension (ESH) in 2023 [11] and by the European Society of Cardiology (ESC) in 2024 [12]. The JSH plans to publish updated guidelines on the management of hypertension in 2025 (JSH2025), and this document is expected to include a strong emphasis on societal implementation of the included recommendations. The JSH 2025 guideline will provide a comprehensive overview of the latest, evidence-based insights regarding the diagnosis and treatment of hypertension, accumulated over decades of research. However, the challenge lies in achieving effective real-world implementation of these recommendations [13].
In the Japanese population, BP control remains sub-optimal compared with global standards. Despite efforts by the JSH to address risky morning hypertension over more than two decades [14,15,16], more than half of all patients being treated for hypertension still fail to achieve adequate BP control (Fig. 3) [17, 18]. To intensify efforts in this regard, the JSH is launching a ‘Morning Hypertension Control Program’, which is designed to ensure stricter home BP management, targeting morning hypertension in particular. In addition, this implementation program project will facilitate the use of home BP monitoring and salt restriction in healthcare and medical fields around the world. The JSH contributes to the Japan Medical Association Database of Clinical Medicine (J-DOME), an ongoing nationwide real-world registry aimed at elucidating current evidence on BP control in Japan.
Prevalence of uncontrolled hypertension defined by office, home, and ambulatory blood pressure (BP) values in medicated patients with hypertension (n = 2731) – baseline data from the HI-JAMP study. Reproduced, with permission, from Kario et al. Hypertens Res 2023; 46: 357–367 [15]. A higher number of medications was associated with a lower rate of uncontrolled office BP but the proportion of patients with uncontrolled morning BP remained at ≈55% even during treatment with ≥2 antihypertensive medications
We encourage JSH members to address unresolved issues such as clinical inertia and adherence to antihypertensive therapy. In this context, they are urged to promote appropriate lifestyle guidance on salt reduction, exercise and sleep duration, and to consider the use of recently introduced antihypertensive medications and new drug combinations. Furthermore, evaluating the clinical adoption of novel non-pharmacological treatments, such as digital therapeutics [6, 7] and renal denervation [19, 20], are recommended. We expect that new findings relating to these approaches and their use in clinical practice will be presented and discussed at JSH annual scientific meetings. In addition, we look forward to multi-disciplinary collaboration across sectors – industry, government, and academia –to advance a diverse array of research efforts.
Notably, the ‘Zero Hypertension City’ community-wide initiatives to hypertension prevention and management of model projects and salt reduction activities using sodium-to-potassium ratios as a guide [21], and the promotion of hypertension management based on home BP monitoring [13, 14] are achieving measurable success in collaboration with local communities. These activities serve as a global model of practical implementation science in hypertension from Japan, and the continued advancement of these initiatives is planned.
Internationalization
To date, the International Society of Hypertension (ISH) has taken the lead in fostering communication and academic collaboration between hypertension societies worldwide [8, 22,23,24]. The JSH has been an active contributor to the ISH, advancing unique and pioneering basic, epidemiological and clinical research, to establish the organization on the global stage. Notably, after the COVID-19 pandemic, JSH hosted the 2022 ISH conference in Kyoto, and the ‘ISH2022 KYOTO Hypertension Zero Declaration’ was issued [25]. This represents a successful and invaluable international meeting experience for the JSH.
As the official journal of JSH, Hypertension Research has solidified its status as an international English-language publication with an impact factor of 4.3 and over 1200 submissions annually. Moving forward, we will continue to strengthen our alliances with the ISH, American Heart Association (AHA), ESH, ESC, and Latin American Society of Hypertension (LASH) to remain at the forefront of global hypertension advancements. Furthermore, in collaboration with the Asian Pacific Society of Hypertension (APSH), the Hypertension Cardiovascular Outcome Prevention and Evidence in Asia (HOPE Asia) Network, and other Asian societies, the JSH aims to showcase distinctive research and effective implementation cases from Asia published in Hypertension Research, thereby accelerating our contributions to the global hypertension community [26,27,28].
Perspectives
Modern hypertension science is rapidly evolving due to a variety of advancements, where the development and innovative application of digital technology aims to address clinical challenges, yielding outcomes that prompt new research questions. In this era of information networks, we anticipate that hypertension research will continue to expand in both breadth and depth. The resulting findings should make a significant contribution to the control of hypertension, both in Japan and globally. By continuing to build on Japan’s unique expertise and advancing evidence-based practice, we aim to make significant strides in hypertension prevention and management worldwide. We look forward to the invaluable support and contributions from JSH members to facilitate the achievement of these goals.
References
Node K, Kishi T, Tanaka A, Itoh H, Rakugi H, Ohya Y, et al. The Japanese Society of Hypertension-Digest of plan for the future. Hypertens Res. 2018;41:989–90.
Rakugi H. Further promotion of “the JSH plan for the future” conscious of new normal after/with COVID-19: message from the new president of the Japanese Society of Hypertension. Hypertens Res. 2021;44:4–6.
Kario K. Digital hypertension towards to the anticipation medicine. Hypertens Res. 2023;46:2503–12.
Abe M, Hirata T, Morito N, Kawashima M, Yoshida S, Takami Y, et al. Smartphone application-based intervention to lower blood pressure: a systematic review and meta-analysis. Hypertens Res. 2024. https://doi.org/10.1038/s41440-024-01939-6.
Kario K. Management of hypertension in the digital era: small wearable monitoring devices for remote blood pressure monitoring. Hypertension. 2020;76:640–50.
Kario K, Harada N, Okura A. Digital therapeutics in hypertension: evidence and perspectives. Hypertension. 2022;79:2148–58.
Kario K, Nomura A, Harada N, Okura A, Nakagawa K, Tanigawa T, et al. Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial. Eur Heart J. 2021;42:4111–22.
Kario K, Williams B, Tomitani N, McManus RJ, Schutte AE, Avolio A, et al. Innovations in blood pressure measurement and reporting technology: International Society of Hypertension position paper endorsed by the World Hypertension League, European Society of Hypertension, Asian Pacific Society of Hypertension, and Latin American Society of Hypertension. J Hypertens. 2024;42:1874–88.
Tsoi K, Yiu K, Lee H, Cheng HM, Wang TD, Tay JC, et al. Applications of artificial intelligence for hypertension management. J Clin Hypertens. 2021;23:568–74.
Stergiou GS, Avolio AP, Palatini P, Kyriakoulis KG, Schutte AE, Mieke S, et al. European Society of Hypertension recommendations for the validation of cuffless blood pressure measuring devices: European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. J Hypertens. 2023;41:2074–87.
Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874–2071.
McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912–4018.
Kario K, Hoshide S, Mogi M. The need for a personalized “implementation hypertension” strategy to facilitate the implementation of the new European Society of Hypertension (2023), European Society of Cardiology (2024) and the upcoming Japanese Society of Hypertension (2025) hypertension guidelines in clinical practice. Hypertens Res. 2024. https://doi.org/10.1038/s41440-024-01927-w.
Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235–481.
Hoshide S, Yano Y, Haimoto H, Yamagiwa K, Uchiba K, Nagasaka S, et al. Morning and evening home blood pressure and risks of incident stroke and coronary artery disease in the japanese general practice population: the Japan morning surge-home blood pressure study. Hypertension. 2016;68:54–61.
Kario K, Saito I, Kushiro T, Teramukai S, Tomono Y, Okuda Y, et al. Morning home blood pressure is a strong predictor of coronary artery disease: the HONEST Study. J Am Coll Cardiol. 2016;67:1519–27.
Kario K, Tomitani N, Hoshide S, Nishizawa M, Yoshida T, Kabutoya T, et al. Different home blood pressure thresholds to predict perfect 24-hour ambulatory blood pressure control in treated hypertension based on an “All-in-One” Device. Hypertension. 2023;80:2464–72.
Kario K, Tomitani N, Nishizawa M, Harada N, Kanegae H, Hoshide S. Concept, study design, and baseline blood pressure control status of the nationwide prospective HI-JAMP study using multisensor ABPM. Hypertens Res. 2023;46:357–67.
Kario K, Kai H, Rakugi H, Hoshide S, Node K, Maekawa Y, et al. Consensus statement on renal denervation by the Joint Committee of Japanese Society of Hypertension (JSH), Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT), and the Japanese Circulation Society (JCS). Hypertens Res. 2024;47:2624–32.
Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, Tsioufis K, et al. Renal denervation lowers nighttime blood pressure in true resistant hypertension. Hypertension. 2024. https://doi.org/10.1161/hypertensionaha.124.23848.
Hisamatsu T, Kogure M, Tabara Y, Hozawa A, Sakima A, Tsuchihashi T, et al. Practical use and target value of urine sodium-to-potassium ratio in assessment of hypertension risk for Japanese: Consensus Statement by the Japanese Society of Hypertension Working Group on Urine Sodium-to-Potassium Ratio. Hypertens Res. 2024. https://doi.org/10.1038/s41440-024-01861-x.
Khan NA, Stergiou GS, Omboni S, Kario K, Renna N, Chapman N, et al. Virtual management of hypertension: lessons from the COVID-19 pandemic-International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension. J Hypertens. 2022;40:1435–48.
Schutte AE, Jafar TH, Poulter NR, Damasceno A, Khan NA, Nilsson PM, et al. Addressing global disparities in blood pressure control: perspectives of the International Society of Hypertension. Cardiovasc Res. 2023;119:381–409.
Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75:1334–57.
Tomaszewski M, Itoh H. ISH2022KYOTO hypertension zero declaration. Hypertens Res. 2023;46:1–2.
Hoshide S, Yamamoto K, Katsurada K, Yano Y, Nishiyama A, Wang JG, et al. Agreement regarding overcoming hypertension in the Asian Hypertension Society Network 2022. Hypertens Res. 2023;46:3–8.
Kario K, Tomitani N, Wang TD, Park S, Li Y, Shin J, et al. Home blood pressure-centered approach - from digital health to medical practice: HOPE Asia Network consensus statement 2023. Hypertens Res. 2023;46:2561–74.
Kario K, Wang JG, Chia YC, Wang TD, Li Y, Siddique S, et al. The HOPE Asia network 2022 up-date consensus statement on morning hypertension management. J Clin Hypertens. 2022;24:1112–20.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Kario K has received grants from A&D, Omron Healthcare, Fukuda Denshi, CureApp, and Sanwa Kagaku Kenkyusho, and honoraria from Daichi Sankyo, Viatris, Novartis, Otsuka Pharmaceuticals, Medtronic, Otsuka Medical Device, and Omron Healthcare.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kario, K., Nishiyama, A., Shibata, S. et al. Digital hypertension, implementation hypertension, and internationalization - 3 pillars of Japanese Society of Hypertension 2024–2026 advancing hypertension science from Japan to the world in the information network era. Hypertens Res 48, 1–5 (2025). https://doi.org/10.1038/s41440-024-02045-3
Received:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41440-024-02045-3
Keywords
This article is cited by
-
Prevalence of hypertension and related factors among suspected hypertensive medical personnel during COVID-19 vaccination
Hypertension Research (2026)
-
“Implementation Hypertension” in the pandemic era: unmasking white-coat effects in healthcare workers
Hypertension Research (2026)
-
Implementation hypertension: a new paradigm for global hypertension control in the JSH 2025, WHO 2025, and AHA/ACC 2025 guideline era
Hypertension Research (2026)
-
Uric acid and hypertension: insights from the joint symposium
Hypertension Research (2025)
-
Synchronizing science and society: JSH2025 Guidelines × “Asakatsu BP” action – Morning Blood Pressure 130 Campaign
Hypertension Research (2025)


